Current concepts of vaccines against serogroup B meningococci (MenB) are mainly based on genetically variable protein antigens. Vaccine efficacy studies for meningococcal disease in developed countries are hampered by the low incidence. Licensure must therefore exclusively rely on clinical trials and laboratory investigation of meningococcal strains. In contrast to capsule polysaccharide vaccines, serum bactericidal assays for technical reasons are limited in their practicability as the surrogate of protection provided by MenB vaccines. Therefore, assays are required for reliable laboratory based assessment of expression of those specific antigen variants that are predicted to be targeted by bactericidal antibodies elicited by the vaccine. The MATS ELISA (MATS, meningococcal antigen typing system) reported recently is an example for such an assay. The paper discusses the pre- and post-licensure application of MATS, the role of reference laboratories, concepts of sustained provision of the assay, external quality assessment, and laboratory twinning.
%0 Journal Article
%1 vogel_use_2012
%A Vogel, Ulrich
%A Stefanelli, Paola
%A Vazquez, Julio
%A Taha, Muhamed-Kheir
%A Claus, Heike
%A Donnelly, John
%D 2012
%J Vaccine
%K Antibodies Antigens Bacterial Bacteriological_Techniques Cross_Reactions Humans Immunologic_Techniques Meningococcal_Vaccines Neisseria_meningitidis Serogroup_B molecular_epidemiology
%P B73--77
%R 10.1016/j.vaccine.2011.12.061
%T The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines
%V 30 Suppl 2
%X Current concepts of vaccines against serogroup B meningococci (MenB) are mainly based on genetically variable protein antigens. Vaccine efficacy studies for meningococcal disease in developed countries are hampered by the low incidence. Licensure must therefore exclusively rely on clinical trials and laboratory investigation of meningococcal strains. In contrast to capsule polysaccharide vaccines, serum bactericidal assays for technical reasons are limited in their practicability as the surrogate of protection provided by MenB vaccines. Therefore, assays are required for reliable laboratory based assessment of expression of those specific antigen variants that are predicted to be targeted by bactericidal antibodies elicited by the vaccine. The MATS ELISA (MATS, meningococcal antigen typing system) reported recently is an example for such an assay. The paper discusses the pre- and post-licensure application of MATS, the role of reference laboratories, concepts of sustained provision of the assay, external quality assessment, and laboratory twinning.
@article{vogel_use_2012,
abstract = {Current concepts of vaccines against serogroup B meningococci ({MenB)} are mainly based on genetically variable protein antigens. Vaccine efficacy studies for meningococcal disease in developed countries are hampered by the low incidence. Licensure must therefore exclusively rely on clinical trials and laboratory investigation of meningococcal strains. In contrast to capsule polysaccharide vaccines, serum bactericidal assays for technical reasons are limited in their practicability as the surrogate of protection provided by {MenB} vaccines. Therefore, assays are required for reliable laboratory based assessment of expression of those specific antigen variants that are predicted to be targeted by bactericidal antibodies elicited by the vaccine. The {MATS} {ELISA} ({MATS}, meningococcal antigen typing system) reported recently is an example for such an assay. The paper discusses the pre- and post-licensure application of {MATS}, the role of reference laboratories, concepts of sustained provision of the assay, external quality assessment, and laboratory twinning.},
added-at = {2013-10-04T09:46:01.000+0200},
author = {Vogel, Ulrich and Stefanelli, Paola and Vazquez, Julio and Taha, Muhamed-Kheir and Claus, Heike and Donnelly, John},
biburl = {https://www.bibsonomy.org/bibtex/21faafe56e915ddacc6f4b80a5bff46d1/ag_vogel},
doi = {10.1016/j.vaccine.2011.12.061},
interhash = {7df10289a94018805f820bdaed0d3a23},
intrahash = {1faafe56e915ddacc6f4b80a5bff46d1},
issn = {1873-2518},
journal = {Vaccine},
keywords = {Antibodies Antigens Bacterial Bacteriological_Techniques Cross_Reactions Humans Immunologic_Techniques Meningococcal_Vaccines Neisseria_meningitidis Serogroup_B molecular_epidemiology},
language = {eng},
month = may,
note = {{PMID:} 22607902},
pages = {B73--77},
timestamp = {2013-10-04T09:46:01.000+0200},
title = {The use of vaccine antigen characterization, for example by {MATS}, to guide the introduction of meningococcus B vaccines},
volume = {30 Suppl 2},
year = 2012
}